Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Nanoscope received NIH support for its first-in-class engineered mechanosensitive channel based gene therapy for glaucoma: Nanoscope received Direct Phase II SBIR grant from National Institutes of Health (NIH) for developing an innovative approach to autonomously regulate pressur

Abstract:
Nanoscope Technologies LLC, a biotechnology company developing gene therapies for treatment of chronic diseases, today announced that it has received $1.5 Million SBIR Direct-to-Phase II grant from NIH in support of its advancement of glaucoma therapy using Engineered Mechanosensitive Channel (EMC). The Nanoscope team has developed EMCs to sensitize cells toward abnormal mechanical stress related to pressure elevation caused by Glaucoma. SBIR Direct-to-Phase II grant award is based on demonstration of feasibility of the technology equivalent to meeting Phase I objectives and providing a solid foundation for the proposed Phase II activity.

Nanoscope received NIH support for its first-in-class engineered mechanosensitive channel based gene therapy for glaucoma: Nanoscope received Direct Phase II SBIR grant from National Institutes of Health (NIH) for developing an innovative approach to autonomously regulate pressur

Arlington, TX | Posted on October 7th, 2022

Vision loss due to glaucoma is the second leading cause of blindness in America, and there is no cure (yet) for glaucoma. Glaucoma is recalcitrant to treatment and the resulting optic nerve damage is irreversible. Primary Open Angle Glaucoma (POAG) is common and is characterized by poor drainage of aqueous humor through the conventional outflow pathway. The currently available pharmacological and surgical treatments for glaucoma have significant limitations and side-effects, which include systemic reactions to medications, patient non-compliance, eye infections, surgical device failure, and damage to the eye.

EMC acts as an ideal drainage valve for trabecular meshwork (TM), because it is a relatively small homo-oligomeric channel and does not need any associated proteins or energy sources to assemble and function. Using patented gene-agnostic EMC therapy, Nanoscope researchers have demonstrated that lowering of the intraocular pressure (IOP) in animal models of glaucoma. "EMC is an engineered version of a stretch-activated channel, which directly senses tension in the membrane lipid bilayer of cells and in response, transiently opens its pore for fluid exchange. Use of EMC in the impaired TM of glaucomatous eyes as an autonomous pressure modulator is novel and has significant promise for Glaucoma", said Samarendra Mohanty, President and Chief Scientific Officer.

POAG is heterogenous, and known to be caused by different genetic mutations, however, most contributing mutations are still unknown. Therefore, Nanoscope’s approach of correcting the pathological phenotype rather than correction of genetic mutation in a gene-independent manner would be transformative in clinical ophthalmology. The development of a safe, effective, long-lasting single dose therapeutic for the treatment of POAG would improve the lives of millions of people suffering from this devastating disease.

####

About Nanoscope Technologies LLC
Nanoscope Technologies, LLC, founded in 2009 by Samarendra Mohanty, PhD., has received several SBIR awards, National Institutes of Health (NIH) R01 grants, and patents which focus on optical stimulation, gene delivery, and imaging for neural activity monitoring. It has spun off several companies Nanoscope Therapeutics Inc, Nanoscope Instruments Inc, Nanoscope Diagnostics LLC and Opsin Biotherapeutics Inc for commercialization of the platform technologies.

For more information, please click here

Contacts:
Media Contact

Sulagna Bhattacharya
Nanoscope Technologies

Office: 626-244-5300
Expert Contact

Samarendra Mohanty
Nanoscope Technologies LLC

Office: 8177192692
Cell: 9494397923
@Nanoscope Technologies LLC

Copyright © Nanoscope Technologies LLC

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Researchers develop artificial building blocks of life March 8th, 2024

How surface roughness influences the adhesion of soft materials: Research team discovers universal mechanism that leads to adhesion hysteresis in soft materials March 8th, 2024

Two-dimensional bimetallic selenium-containing metal-organic frameworks and their calcinated derivatives as electrocatalysts for overall water splitting March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

Govt.-Legislation/Regulation/Funding/Policy

What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024

Researchers’ approach may protect quantum computers from attacks March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Optically trapped quantum droplets of light can bind together to form macroscopic complexes March 8th, 2024

Possible Futures

Two-dimensional bimetallic selenium-containing metal-organic frameworks and their calcinated derivatives as electrocatalysts for overall water splitting March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024

Nanomedicine

High-tech 'paint' could spare patients repeated surgeries March 8th, 2024

Researchers develop artificial building blocks of life March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Announcements

What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024

Nanobiotechnology

High-tech 'paint' could spare patients repeated surgeries March 8th, 2024

Researchers develop artificial building blocks of life March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project